Stock Track | TG Therapeutics Soars 5.12% Intraday on Strong Earnings and Raised 2026 Revenue Guidance

Stock Track02-27

TG Therapeutics' stock price surged 5.12% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The biopharmaceutical company reported robust growth, driven primarily by its multiple sclerosis treatment BRIUMVI. U.S. net product revenue for BRIUMVI grew 20% quarter-over-quarter to $182.7 million in Q4 and surged 92% year-over-year for the full year to $594.1 million. The company also raised its 2026 financial outlook, targeting total global revenue of $875 to $900 million, including BRIUMVI U.S. net product revenue of $825 to $850 million. Additionally, TG Therapeutics highlighted the completion of a $100 million share repurchase program and the authorization of a new $100 million buyback program, alongside positive clinical pipeline updates and global expansion of BRIUMVI.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102372937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102372937","market":"hk","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Soars 5.12% Intraday on Strong Earnings and Raised 2026 Revenue Guidance","media":"Stock Track","content":"<p>TG Therapeutics' stock price surged 5.12% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported robust growth, driven primarily by its multiple sclerosis treatment BRIUMVI. U.S. net product revenue for BRIUMVI grew 20% quarter-over-quarter to $182.7 million in Q4 and surged 92% year-over-year for the full year to $594.1 million. The company also raised its 2026 financial outlook, targeting total global revenue of $875 to $900 million, including BRIUMVI U.S. net product revenue of $825 to $850 million. Additionally, TG Therapeutics highlighted the completion of a $100 million share repurchase program and the authorization of a new $100 million buyback program, alongside positive clinical pipeline updates and global expansion of BRIUMVI.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Soars 5.12% Intraday on Strong Earnings and Raised 2026 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Soars 5.12% Intraday on Strong Earnings and Raised 2026 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 01:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics' stock price surged 5.12% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported robust growth, driven primarily by its multiple sclerosis treatment BRIUMVI. U.S. net product revenue for BRIUMVI grew 20% quarter-over-quarter to $182.7 million in Q4 and surged 92% year-over-year for the full year to $594.1 million. The company also raised its 2026 financial outlook, targeting total global revenue of $875 to $900 million, including BRIUMVI U.S. net product revenue of $825 to $850 million. Additionally, TG Therapeutics highlighted the completion of a $100 million share repurchase program and the authorization of a new $100 million buyback program, alongside positive clinical pipeline updates and global expansion of BRIUMVI.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1102372937","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102372937","pubTimestamp":1772126973,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics' stock price surged 5.12% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics盘中大涨5.12%盈利强劲上调2026年营收指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics' stock price surged 5.12% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical company reported robust growth, driven primarily by its multiple sclerosis treatment BRIUMVI. U.S. net product revenue for BRIUMVI grew 20% quarter-over-quarter to $182.7 million in Q4 and surged 92% year-over-year for the full year to $594.1 million. The company also raised its 2026 financial outlook, targeting total global revenue of $875 to $900 million, including BRIUMVI U.S. net product revenue of $825 to $850 million. Additionally, TG Therapeutics highlighted the completion of a $100 million share repurchase program and the authorization of a new $100 million buyback program, alongside positive clinical pipeline updates and global expansion of BRIUMVI.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102372937","isCrawlerRequest":true}